What can patent data reveal about global progress in green innovation, and what might be achieved in years to come?
A new EPO referral to the enlarged BoA will determine whether post-filed data can be used to support inventive step and plausibility.
The Greenshoots Podcast by Appleyard Lees – episode 20: Doctrine of equivalents and its impact on patent infringement assessment in the UK
In 2017, the UK Supreme Court’s judgement of Actavis v Eli Lilly created significant change to the way patent infringement is assessed in the UK by introducing a formal doctrine of equivalents. Four years on, Appleyard Lees partners and patent attorneys Adam Tindall and David Walsh, and senior associate and patent attorney Chris Mason discuss […]
As provided in the recent UK budget announcement, the UK corporation tax rate is set to rise from 19 to 25 percent from 1 April 2023. As a result, companies should now be thinking about whether they can make use of the tax relief provided by the Patent Box scheme.
There are many sectors in which companies are inventing and patenting green technologies. In the chemical field, there is considerable activity in relation to carbon dioxide gas reduction, developing sustainable non-polluting processes and using alternatives to fossil fuels.
Tech transfer teams’ IP challenges post-COVID-19 and beyond: part three how much data is enough in biotech and pharma patents applications?
‘Tech transfer teams’ IP challenges post-COVID-19 and beyond’ is a series of interactive virtual discussions, focused on unpacking the issues relevant to those managing intellectual property for tech transfer departments. In part three Barbara Fleck and David Walsh examine the requirements for sufficiency and plausibility at the EPO and provide practical advice on drafting robust applications. […]
In this judgment at the High Court, Lord Justice Arnold stepped down from the Court of Appeal to the High Court to hear the case. His findings on infringement may be an indication of Arnold’s desire to set some practical limits on the first and third Actavis equivalence questions. In particular, he applies a rigorous […]
In a recent decision (Warner-Lambert Company LLC v Generics Ltd t/a Mylan and Actavis Group), the Supreme Court has rejected an appeal by Warner-Lambert against a High Court and subsequent Court of Appeal decision regarding the invalidity and infringement of their patent. The patent at issue (EP 0934061) relates to the use of pregabalin for […]